BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/14/2020 12:30:24 PM | Browse: 791 | Download: 1581
 |
Received |
|
2019-12-12 02:43 |
|
Peer-Review Started |
|
2019-12-12 02:44 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-01-19 02:54 |
|
Revised |
|
2020-01-20 15:34 |
|
Second Decision |
|
2020-03-08 12:52 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-03-09 06:57 |
|
Articles in Press |
|
2020-03-09 06:57 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-03-26 23:43 |
|
Typeset the Manuscript |
|
2020-04-13 10:03 |
|
Publish the Manuscript Online |
|
2020-04-14 12:30 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Opinion Review |
| Article Title |
Optimized timing of using infliximab in perianal fistulizing Crohn's disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Xue-Liang Sun, Shi-Yi Chen, Shan-Shan Tao, Li-Chao Qiao, Hong-Jin Chen and Bo-Lin Yang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81673973 |
| 333 Project of Jiangsu Province, China |
LGY2019069 |
| Developing Program for High-level Academic Talent in Jiangsu Hospital of TCM |
y2018rc16 |
| Postgraduate Research and Practice Innovation Program of Jiangsu Province |
SJCX18_0510 |
| Open Projects of the Discipline of Nanjing University of Chinese Medicine supported by Academic Priority discipline of Jiangsu Higher Education Institutions |
|
|
| Corresponding Author |
Bo-Lin Yang, MD, Chief Doctor, Professor, Surgeon, Department of Colorectal Surgery, The Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, Nanjing 210029, Jiangsu Province, China. yfy0051@njucm.edu.cn |
| Key Words |
Infliximab; Crohn’s disease; Perianal fistula; Optimization; Trough level; Deep remission |
| Core Tip |
The long-term outcomes of infliximab in the treatment of perianal fistulizing Crohn’s disease are unfavorable, due to loss of response. The optimization of the therapeutic strategy may increase clinical remission. Higher infliximab concentrations during induction are associated with a complete fistula response. Only patients in prolonged clinical remission should be considered for withdrawal of infliximab when biomarker, endoscopic and radiological remission is demonstrated. Fundamentally, the optimal timing of infliximab use is highly individualized and should be determined by a multidisciplinary team. |
| Publish Date |
2020-04-14 12:30 |
| Citation |
Sun XL, Chen SY, Tao SS, Qiao LC, Chen HJ, Yang BL. Optimized timing of using infliximab in perianal fistulizing Crohn's disease. World J Gastroenterol 2020; 26(14): 1554-1563 |
| URL |
https://www.wjgnet.com/1007-9327/full/v26/i14/1554.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v26.i14.1554 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
